Parkinsonism & related disorders最新文献

{"title":"Correcting vertical perception to reverse Pisa syndrome in Parkinson's disease: A case report","authors":"Hanhong Jiang , Wangqingyuan Wang , Qingchuan Wei , Liyi Huang , Saiqing Ye , Qiang Gao","doi":"10.1016/j.parkreldis.2025.108012","DOIUrl":"10.1016/j.parkreldis.2025.108012","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108012"},"PeriodicalIF":3.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between prior allergic rhinitis and Parkinson's disease","authors":"Tzong-Hann Yang ,&nbsp;Yen-Fu Cheng ,&nbsp;Herng-Ching Lin ,&nbsp;Chin-Shyan Chen","doi":"10.1016/j.parkreldis.2025.108013","DOIUrl":"10.1016/j.parkreldis.2025.108013","url":null,"abstract":"<div><h3>Introduction</h3><div>A growing body of evidence suggests that chronic inflammation may be a key contributor to Parkinson's disease (PD) pathogenesis. This study aimed to investigate whether a prior history of allergic rhinitis (AR) is associated with an elevated risk of developing PD by utilizing Taiwan's nationwide health insurance claims database.</div></div><div><h3>Methods</h3><div>We retrieved data for this case-control study from the Taiwan Longitudinal Health Insurance Database 2010. This study included 16,611 individuals aged ≥50 years old who received a first-time diagnosis of PD as cases and 49,833 propensity-score-matching controls. To evaluate the association between prior AR and PD, multivariable logistic regression models were employed to calculate adjusted odds ratios (ORs) along with 95 % confidence intervals (CIs).</div></div><div><h3>Results</h3><div>In unadjusted analysis, we found that prior AR was significantly more prevalent among patients with PD than among controls (26.55 % vs. 20.72 %, OR = 1.38, 95 % CI: 1.33–1.44, <em>p</em> &lt; 0.001). This association remained statistically significant and similar in magnitude in the multivariable model after adjustment for age, sex, monthly income, geographic region, level of urbanization, hypertension, diabetes, hyperlipidemia, hearing loss, and coronary heart disease (OR = 1.40; 95 % CI: 1.34–1.46, <em>p</em> &lt; 0.001).</div></div><div><h3>Discussions</h3><div>This population-based analysis provides evidence supporting a substantive association between AR and an increased risk of PD. These results suggest that AR should be recognized not only as a widely prevalent inflammatory disorder but also as a potential contributor to neurodegenerative pathophysiology.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108013"},"PeriodicalIF":3.4,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-onset non-kinesigenic paroxysmal dyskinesia in GLUT1 deficiency syndrome","authors":"José Miguel Alves ,&nbsp;Rita Machado ,&nbsp;Maria Carmo Macário ,&nbsp;João Durães","doi":"10.1016/j.parkreldis.2025.108011","DOIUrl":"10.1016/j.parkreldis.2025.108011","url":null,"abstract":"<div><div>Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a disorder caused by variants in the SLC2A1 gene. Clinical features are heterogeneous, from the classic presentation to milder later-onset phenotypes. We describe the case of a male patient with adult-onset paroxysmal dyskinesia in a mild phenotype of GLUT1DS (NM_006516.4 c.998G &gt; A, p. Arg333Gln).</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108011"},"PeriodicalIF":3.4,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TMEM151A-related Paroxysmal Kinesigenic Dyskinesia in first two Indian families","authors":"Revathi Sampath ,&nbsp;Prabhakara Somanna ,&nbsp;Anbazhagan Kolandaswamy ,&nbsp;Sahana Rajashekhar ,&nbsp;Prashanth Lingappa Kukkle","doi":"10.1016/j.parkreldis.2025.108010","DOIUrl":"10.1016/j.parkreldis.2025.108010","url":null,"abstract":"<div><div>The pathogenic variants of <em>TMEM151A</em> are known to be the genetic cause for Paroxysmal Kinesigenic Dyskinesia apart from <em>PRRT2</em> variants. Through whole exome sequencing, we identified a known variant (c.368G &gt; C; p. Arg123Pro) in the affected siblings of family-1 and a novel heterozygous variant (c.335T &gt; C; p. Leu112Pro) in the patient of family-2.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108010"},"PeriodicalIF":3.4,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of T1-Weighted MRI gray matter biomarkers in Parkinson's disease: A systematic review and meta-analysis.","authors":"Alejandra Torres-Parga, Oscar Gershanik, Sebastian Cardona, Jairo Guerrero, Lina M Gonzalez-Ojeda, Juan F Cardona","doi":"10.1016/j.parkreldis.2025.108009","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.108009","url":null,"abstract":"<p><strong>Background: </strong>T1-weighted structural MRI has advanced our understanding of Parkinson's disease (PD), yet its diagnostic utility in clinical settings remains unclear.</p><p><strong>Objective: </strong>To assess the diagnostic performance of T1-weighted MRI gray matter (GM) metrics in distinguishing PD patients from healthy controls and to identify limitations affecting clinical applicability.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted on studies reporting sensitivity, specificity, or AUC for PD classification using T1-weighted MRI. Of 2906 screened records, 26 met inclusion criteria, and 10 provided sufficient data for quantitative synthesis. The risk of bias and heterogeneity were evaluated, and sensitivity analyses were performed by excluding influential studies.</p><p><strong>Results: </strong>Pooled estimates showed a sensitivity of 0.71 (95 % CI: 0.70-0.72), specificity of 0.889 (95 % CI: 0.86-0.92), and overall accuracy of 0.909 (95 % CI: 0.89-0.93). These metrics improved after excluding outliers, reducing heterogeneity (I² = 95.7 %-0 %). Frequently reported regions showing structural alterations included the substantia nigra, striatum, thalamus, medial temporal cortex, and middle frontal gyrus. However, region-specific diagnostic metrics could not be consistently synthesized due to methodological variability. Machine learning approaches, particularly support vector machines and neural networks, showed enhanced performance with appropriate validation.</p><p><strong>Conclusions: </strong>T1-weighted MRI gray matter metrics demonstrate moderate accuracy in differentiating PD from controls but are not yet suitable as standalone diagnostic tools. Greater methodological standardization, external validation, and integration with clinical and biological data are needed to support precision neurology and clinical translation.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"108009"},"PeriodicalIF":3.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between VMAT2-PET and DAT-SPECT caudate binding and Parkinson's disease cognitive decline","authors":"Mohammad Hamo ,&nbsp;Nicole Anyanwu ,&nbsp;Isabel Long ,&nbsp;Rishabh Gupta ,&nbsp;Rocio Bermudez ,&nbsp;Deeptha Subramanian ,&nbsp;Helen Qian ,&nbsp;Kaltra Dhima ,&nbsp;Sarah K. Bick","doi":"10.1016/j.parkreldis.2025.108008","DOIUrl":"10.1016/j.parkreldis.2025.108008","url":null,"abstract":"<div><h3>Introduction</h3><div>Dopamine transporter (DAT) imaging can help diagnose Parkinson's disease (PD), and decreased caudate binding predicts cognitive decline. Studies suggest vesicular monoamine transporter type 2 (VMAT2) imaging is more sensitive in detecting striatal changes associated with PD motor symptoms. Our hypothesis is that lower VMAT2 caudate binding is correlated with future cognitive decline in PD.</div></div><div><h3>Methods</h3><div>We utilized clinical and imaging data from the Parkinson's Progression Markers Initiative (PPMI). We evaluated the relationship between baseline VMAT2 and DAT caudate binding and future change in Montreal Cognitive Assessment (MoCA) score using linear regression. To evaluate localization of findings we performed similar analysis with VMAT2 and DAT putamen and most and least affected caudate binding. We also categorized patients into groups of normal and reduced VMAT2 and DAT caudate binding and compared baseline and follow up characteristics between groups.</div></div><div><h3>Results</h3><div>Among 54 subjects with follow up data, baseline VMAT2 caudate binding correlated with change in MoCA score, while DAT did not (r = 0.280, p = 0.0164 and r = 0.189, p = 0.410 respectively). Baseline VMAT2 putamen binding also correlated with change in MoCA score (p = 0.0236, r = 0.23). Reduced VMAT2 caudate binding groups had higher motor severity score at baseline and lower cognitive scores on follow-up (p = 0.0015), while DAT did not (p = 0.174). Patients with reduced VMAT2 caudate but not putamen binding had significantly greater decline in MoCA score (caudate p = 0.0015, putamen p = 0.179).</div></div><div><h3>Conclusion</h3><div>Reduced caudate VMAT2 binding may predict future cognitive decline, and in our patient population, was more sensitive than caudate DAT binding in predicting the magnitude of decline.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108008"},"PeriodicalIF":3.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of cognitive reserve on cognitive function and cognitive deterioration in Parkinson's disease: a longitudinal cohort study","authors":"Lihua Gu ,&nbsp;Pengcheng Zhang ,&nbsp;Wenchao Zuo ,&nbsp;Hao Shu","doi":"10.1016/j.parkreldis.2025.108001","DOIUrl":"10.1016/j.parkreldis.2025.108001","url":null,"abstract":"<div><h3>Background</h3><div>Previous cross-sectional work has suggested that higher cognitive reserve (CR) is associated with better cognitive performance and slower cognitive decline in Parkinson's disease (PD); however, these findings need confirmation in prospective longitudinal designs. The current study therefore examined how CR influences both cognitive function and the rate of cognitive deterioration in a longitudinal PD cohort.</div></div><div><h3>Methods</h3><div>This study utilized a prospective, longitudinal design and recruited participants from Tianjin Huanhu Hospital between September 2017–September 2019. PD patients were followed up for clinical assessment at an average of 2 ± 0.6 years.</div></div><div><h3>Results</h3><div>Higher CR levels were associated with better cognitive performance and reduced cognitive decline over a 2-year follow-up period. Linear regression analysis revealed significant positive associations between CR and the 2-year change rate of Montreal cognitive assessment (MoCA) scores, with age and apolipoprotein E (APOE) genotype being significant predictors. Logistic regression indicated that CR Index (CRI) components (education, working activity, and leisure time) and intelligence quotient (IQ) were independently associated with cognitive decline risk.</div></div><div><h3>Conclusions</h3><div>The study highlights the importance of CR in mitigating cognitive decline in PD and suggests that interventions to enhance CR could be beneficial for PD patients. Future research should focus on elucidating the underlying mechanisms and developing targeted interventions to support cognitive health in PD.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108001"},"PeriodicalIF":3.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144889997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to Editor on “Circulating cell-free DNA as predictors of Parkinson's disease”","authors":"Simon Geir Møller","doi":"10.1016/j.parkreldis.2025.108004","DOIUrl":"10.1016/j.parkreldis.2025.108004","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108004"},"PeriodicalIF":3.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Monteiro et al.: MR-guided focused ultrasound for essential tremor with low skull density ratio—Independent meta-analysis and clinical implications","authors":"Matthan Tharakan,&nbsp;Andrew K. Conner","doi":"10.1016/j.parkreldis.2025.108003","DOIUrl":"10.1016/j.parkreldis.2025.108003","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108003"},"PeriodicalIF":3.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144886681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease","authors":"Kevin Oliveira Hauer ,&nbsp;Sara Hall ,&nbsp;Adjmal Nahimi ,&nbsp;Olof Strandberg ,&nbsp;Tomas Ohlsson ,&nbsp;Jonas Jögi ,&nbsp;Erik Stomrud ,&nbsp;Shorena Janelidze ,&nbsp;Oskar Hansson ,&nbsp;Ruben Smith","doi":"10.1016/j.parkreldis.2025.108005","DOIUrl":"10.1016/j.parkreldis.2025.108005","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuromelanin containing cell loss, neuroinflammation and synaptic dysfunction are believed to contribute to Parkinson's disease (PD) pathogenesis. [¹⁸F]DOPA PET reflects dopamine storage capacity in the putamen, while midbrain off-target retention of [¹⁸F]RO948 is hypothesized to reflect neuromelanin.</div></div><div><h3>Objectives</h3><div>To investigate associations between disease duration, cerebrospinal fluid (CSF) markers of neurodegeneration, synaptic dysfunction, neuroinflammation, and dopamine synaptic loss as measured by [¹⁸F]DOPA PET in PD patients. We further aimed to explore whether reduced midbrain retention of [¹⁸F]RO948 relates to [¹⁸F]DOPA PET and CSF markers.</div></div><div><h3>Methods</h3><div>Participants were part of the BioFINDER studies. CSF biomarkers were analyzed for controls (n = 623), PD participants (n = 226) and Dementia with Lewy bodies (DLB; n = 33). [¹⁸F]RO948 PET was performed in controls (n = 514), PD (n = 77) and DLB (n = 47) and [¹⁸F]DOPA PET in PD (n = 58) and DLB (n = 22).</div></div><div><h3>Results</h3><div>PD patients showed higher CSF neurofilament light (NfL) levels (pg/ml [mean ± SD] 159 ± 139) vs. controls (137 ± 90, p &lt; 0.001), and lower neurogranin (pg/ml [mean ± SD] 620 ± 255) vs (772 ± 283, p &lt; 0.001). Lower [¹⁸F]DOPA uptake correlated with longer disease duration (ρ = −0.46, p &lt; 0.001), higher NfL (ρ = −0.39, p = 0.03), lower neurogranin (ρ = 0.50, p = 0.003) and NPTX2 levels (ρ = 0.36, p = 0.049). We found no associations between neuroinflammatory markers and [¹⁸F]DOPA PET. Substantia nigra [¹⁸F]RO948 signal was lower in PD ([mean ± SD] 1.67 ± 0.22) vs controls (1.76 ± 0.3, p &lt; 0.001) but did not correlate with disease duration, CSF markers or [¹⁸F]DOPA-PET.</div></div><div><h3>Conclusions</h3><div>In PD patients, a decrease in [¹⁸F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [¹⁸F]RO948 PET midbrain off-target retention.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"139 ","pages":"Article 108005"},"PeriodicalIF":3.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}